Milena Gurgel Teles

Milena Gurgel Teles

Auto-generated profile, based on publicly available information

Milena Gurgel Teles

Grupo de Diabetes Monogênico (Monogenic Diabetes Group), Unidade de Endocrinologia Genética (LIM25), Unidade de Diabetes, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
CFCamila Kruschewsky Falcao
Camila Kruschewsky Falcao
MCMarina Campos Simoes Cabral
Marina Campos Simoes Cabral
JMJose Mauricio Mota
Jose Mauricio Mota
SASamia Trigo Arbache
Samia Trigo Arbache
ACAline Dantas Costa-Riquetto
Aline Dantas Costa-Riquetto
MTMilena Gurgel Teles
Milena Gurgel Teles
Context Lipodystrophy syndromes are rare disorders characterized by the selective loss of adipose tissue. We aimed to report the first case of acquired generalized lipodystrophy possibly associated with nivolumab. Case Description A woman was referred to our Endocrinology Department for uncontrolled diabetes mellitus. At 50 years of age, she was diagnosed with type 2 diabetes after a routine laboratory test and her diabetes was well controlled with low doses of metformin. In 2010, she was diagnosed with clear cell renal carcinoma. The cancer progressed in the following years, leading to the initiation of treatment with nivolumab in 2017. Two months later she presented with facial lipoatrophy, with loss of the buccal fat pads and prominent zygomatic arche. Her neck, shoulders, arms and buttocks were also affected. Her diabetes control worsened. She received maximal doses of metformin and pioglitazone and was administered 1.5 units/kg/day insulin. Subcutaneous biopsy of medial surface of the arm revealed chronic lobular panniculitis. Despite nivolumab’s possible involvement in the onset of lipodystrophy, the maintenance of nivolumab therapy was justified by the observed reduction in the progression of the cancer, combined with the lack of an alternative chemotherapy. The therapy was withdrawn after eight months of treatment because of grade 3 hepatitis. Conclusion Anti-PD1 therapy has great potential. Early recognition of the onset of unusual collateral effects is important to improve decision making regarding the treatment of patients with tumors.

19 July 2017 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
LCL.A. Caetano
L.A. Caetano
LSL.S. Santana
L.S. Santana
ACA.D. Costa‐Riquetto
A.D. Costa‐Riquetto
ALAntonio Marcondes Lerario
Antonio Marcondes Lerario
MNM. Nery
M. Nery
MTM.G. Teles
M.G. Teles

1 October 2011 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MTMilena Gurgel Teles
Milena Gurgel Teles
LSLeticia Ferreira Gontijo Silveira
Leticia Ferreira Gontijo Silveira
CTCintia Tusset
Cintia Tusset
ALAna Claudia Latronico
Ana Claudia Latronico

8 October 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
LSLucas S. de Santana
Lucas S. de Santana
LCLilian A. Caetano
Lilian A. Caetano
ACAline D. Costa‐Riquetto
Aline D. Costa‐Riquetto
PFPedro C. Franco
Pedro C. Franco
RDRenata P. Dotto
Renata P. Dotto
MTMilena G. Teles
Milena G. Teles
Background: Maturity‐onset diabetes of the young (MODY) is a form of monogenic diabetes with autosomal dominant inheritance. To date, mutations in 11 genes have been frequently associated with this phenotype. In Brazil, few cohorts have been screened for MODY, all using a candidate gene approach, with a high prevalence of undiagnosed cases (MODY‐X).Methods: We conducted a next‐generation sequencing target panel (tNGS) study to investigate, for the first time, a Brazilian cohort of MODY patients with a negative prior genetic analysis. One hundred and two patients were selected, of which 26 had an initial clinical suspicion of MODY‐GCK and 76 were non‐GCK MODY.Results: After excluding all benign and likely benign variants and variants of uncertain significance, we were able to assign a genetic cause for 12.7% (13/102) of the probands. Three rare MODY subtypes were identified (PDX1/NEUROD1/ABCC8), and eight variants had not been previously described/mapped in genomic databases. Important clinical findings were evidenced in some cases after genetic diagnosis, such as MODY‐PDX1/HNF1B.Conclusion: A multiloci genetic approach allowed the identification of rare MODY subtypes, reducing the large percentage of MODY‐X in Brazilian cases and contributing to a better clinical, therapeutic, and prognostic characterization of these rare phenotypes.

7 February 2017 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
LSL.S. Santana
L.S. Santana
LCL.A. Caetano
L.A. Caetano
ACA.D. Costa‐Riquetto
A.D. Costa‐Riquetto
EQE.P.S. Quedas
E.P.S. Quedas
MNM. Nery
M. Nery
MTM.G. Teles
M.G. Teles

16 July 2025 in Diabetologia
Verified
Journal Article
Open access
PDF file
JRJames Russ-Silsby
James Russ-Silsby
MTMilena Teles
Milena Teles
SHSamar Sabir Hassan
Samar Sabir Hassan
NENancy S. Elbarbary
Nancy S. Elbarbary
NCNgoc Thi Bich Can
Ngoc Thi Bich Can
EFElisa De Franco
Elisa De Franco
Monogenic forms of diabetes represent an uncommon but very heterogeneous subset of the disease, with variable associated clinical features and key differences in treatment options. In this review, we discuss how advances in precision medicine and genomic sequencing have enhanced our understanding of the aetiology and clinical variability of monogenic diabetes. We highlight current global challenges, including the over-representation of individuals of European genetic ancestry in research studies, which complicates diagnosis in non-European populations, and national disparities in genetic testing strategies, which influence diagnostic accuracy. Additionally, we address issues in variant interpretation stemming from the increased understanding of variable penetrance in monogenic diabetes and the need to expand current reference datasets to exclude common genetic variation. Finally, we explore future directions, including the potential benefits of ongoing genetic studies for under-represented populations, the benefits and potential pitfalls of newborn screening programmes, and the potential of stem cell-derived islet transplantation and glucagon-like peptide- 1 receptor agonists as treatments for some forms of monogenic diabetes. Graphical Abstract